Skip to main content
. 2020 Nov 12;13:4115–4123. doi: 10.2147/IDR.S268744

Table 1.

Demographic, Clinical Characteristics and Outcomes of 215 Patients with P. aeruginosa Bacteremiaa

Characteristics Total N=215 Died N=61 Alive N=154 OR 95% CI P-value
Age (years), (mean, SD) 60.5, 19.0 65.1, 16.1 58.7, 19.8 0.016
Male gender, n (%) 159 (74.0) 47 (77.0) 112 (72.7) 1.259 0.629–2.520 0.515
Underlying disease, n (%) 154 (71.6) 59 (96.7) 95 (61.7) 18.321 4.314–77.806 <0.001
Diabetes mellitus 54 (25.1) 21 (34.4) 33 (21.4) 1.925 1.001–3.701 0.048
Chronic lung disease 35 (16.3) 19 (31.1) 16 (10.4) 3.902 1.844–8.255 <0.001
Chronic renal failure 22 (10.2) 5 (8.2) 17 (11.0) 0.720 0.253–2.045 0.535
Liver disease 29 (13.5) 1 (1.6) 28 (18.2) 0.075 0.010–0.564 0.003
Solid organ cancer 39 (18.1) 9 (14.8) 30 (19.5) 0.715 0.318–1.612 0.418
Cardiovascular disease 81 (37.7) 42 (68.9) 39 (25.3) 6.518 3.395–12.515 <0.001
Solid-organ transplantation 3 (1.4) 1 (1.6) 2 (1.3) 1.267 0.113–14.230 1.000
Hematological Disease 50 (23.3) 11 (18.0) 39 (25.3) 0.649 0.307–1.369 0.254
Benign biliary tract disease 32 (14.9) 2 (3.3) 30 (19.5) 0.140 0.032–0.606 0.005
Primary site of infection, n (%)
 Lung 64 (29.8) 32 (52.5) 32 (20.8) 4.207 2.228–7.944 <0.001
 Soft-tissue 2 (0.9) 1 (1.6) 1 (0.6) 2.550 0.157–41.427 1.000
 Biliary tract 12 (5.6) 0 (0.0) 12 (7.8) 1.085 1.036–1.135 0.021
 Urinary tract 10 (4.7) 0 (0.0) 10 (6.5) 1.069 1.026–1.115 0.066
 Catheter-related 48 (22.3) 8 (13.1) 40 (26.0) 0.430 0.188–0.983 0.041
 Peritoneum 9 (4.2) 0 (0.0) 9 (5.8) 1.062 1.021–1.105 0.063
 Unknown 70 (32.6) 20 (32.8) 50 (32.5) 1.015 0.539–1.909 0.964
Nosocomial infectionb, n (%) 176 (81.9) 49 (80.3) 127 (82.5) 0.868 0.408–1.848 0.714
Comorbid condition, n (%)
Corticosteroid use 60 (27.9) 15 (24.6) 45 (29.2) 0.790 0.401–1.557 0.495
 Immune deficiencyc 54 (25.1) 10 (16.4) 44 (28.6) 0.490 0.229–1.051 0.063
 Neutropeniad 40 (18.6) 10 (16.4) 30 (19.5) 0.810 0.369–1.779 0.600
 Intravenous catheterization 146 (67.9) 20 (32.8) 126 (81.8) 0.108 0.055–0.213 <0.001
 Blood transfusion 87 (40.5) 33 (54.1) 54 (35.1) 2.183 1.195–3.987 0.010
 Coinfection with other bacteria 44 (20.5) 18 (29.5) 26 (16.9) 2.061 1.030–4.122 0.039
Hospitals, n (%)
 CJFH 69 (32.1) 42 (68.9) 27 (17.5) 10.398 5.253–20.581 <0.001
 Henan Provincial People’s Hospital 79 (36.7) 2 (3.3) 77 (50.0) 0.034 0.008–0.144 <0.001
 Ningbo Medical Center Lihuili Hospital 30 (14.0) 6 (9.8) 24 (15.6) 0.591 0.229–1.526 0.273
 Wuhan Forth Hospital 36 (16.7) 11 (18.0) 25 (16.2) 1.135 0.520–2.478 0.750
 Weifang No.2 People’s Hospital 1 (0.5) 0 (0.0) 1 (0.6) 1.007 0.994–1.019 1.000
Antimicrobial therapy regimen, n (%) 209 (97.2) 60 (98.4) 149 (96.8) 2.013 0.230–17.596 0.853
 Monotherapye 91 (42.3) 18 (29.5) 73 (47.4) 0.464 0.246–0.876 0.017
 Combined antibiotic therapyf 118 (54.9) 42 (68.9) 76 (49.4) 2.269 1.212–4.248 0.010
LOS (days), median (IQR) 20.0 (12.0–31.8) 14.0
(9.0–31.0)
22.0
(14.0–32.0)
0.422
Received mechanical ventilation, n (%) 69 (32.1) 43 (70.5) 26 (16.9) 11.761 5.880–23.522 <0.001
Admitted to ICU, n (%) 88 (40.9) 51 (83.6) 37 (24.0) 16.127 7.451–34.904 <0.001

Notes: aP. aeruginosa bacterium was defined as the presence of P. aeruginosa in blood culture and the clinical features related to the P. aeruginosa infection. Only the first P. aeruginosa bacterium event was enrolled in the analysis if a patient presented ≥2 positive P. aeruginosa bacteremia during the study period. bNosocomial infection was defined as the occurrence of P. aeruginosa bacterium (1) that occurred more than 48 h after admission to hospital (2) that occurred less than 48 h after admission to hospital in cases who had been in other hospitals within the 2 weeks prior to admission. cThe presence of immune deficiency was defined as the receipt of immunosuppressive therapy (immunosuppressive agent, chemotherapy or radiotherapy) during the P. aeruginosa bacteremia. dNeutropenia was defined that an absolute neutrophil count of <500/mL. eAntibiotic monotherapy was defined as the treatment with only one of the following antibiotics: aztreonam, cefoperazone-sulbactam, ceftazidime, ticarcillin-clavulanate, piperacillin-tazobactam, cefepime, imipenem, meropenem, amikacin, levofloxacin, ciprofloxacin, colistin, and so on. fCombination therapy consisted of the treatment with two or more antibiotics.

Abbreviations: SD, standard deviation; IQR, interquartile range; ICU, intensive care unit; LOS, length of hospital stay; CJFH, China-Japan Friendship Hospital; OR, odds ratio; CI, confidence interval.